

August 6, 2002

Dockets Management Branch (HFA-305)
Food and Drug Administration
5630 Fishers Lane, Room 1061
Rockville, MD 20852

Docket No. 02N-0204

UDL Laboratories, Inc. is a wholly owned subsidiary of Mylan Laboratories, Inc. and is known by thousands of health care providers throughout the nation as a leading repackager, marketer and supplier of multi-source unit dose pharmaceutical products for the institutional marketplace. More than 5,000 hospitals and long term care providers nationwide know UDL as the nation's largest supplier of generic unit dose pharmaceuticals. In fact, we market more generic pharmaceuticals in unit dose form than any other single source and repackager in excess of 900 million individual doses per year.

Easy to read packaging is an important safety factor in reducing drug administration errors. UDL offers consistent, highly legible labeling as well as space saving package design for all our oral solid products. We have led the generic industry in printing NDC format scannable bar codes on the individual unit dose blister. We have integrated bar code labeling at all levels of our packaging which adheres to the Health Industry Business Communication Council standards.

UDL is committed to patient health, patient safety and providing quality products to the hospital marketplace. We support any efforts to improve these in all pharmaceutical sectors. Consistent with this commitment, we firmly support the use of standardized bar code labeling for human drug products to aid in the reduction of medication errors.

Attached please find our response to the questions found in Docket No. 02N-0204, Bar Code Label Requirements for Human Drug Products; Notice of Public Meeting, Vol. 67 No. 117, Tuesday, June 18, 2002.

Thank you for the opportunity to provide these comments.

Sincerely Yours,

Vincent Mancinelli II

VINCENT MANCINELLI II
Vice President Quality and Regulatory Affairs, UDL Laboratories

02N-0204

C11



TABLE OF CONTENTS

- I. Response to Docket No. 02N-0204 - FDA Bar Code Label Requirements for Human Drug Products
- II. Attachment A
- III. Attachment B
- IV. Attachment C